English
French
Press Release
|
18 |
Dec 2017 |
IntelGenx Site Obtains GMP Compliant Rating From Health Canada for Manufacturing and Packaging Activities... |
|
15 |
Dec 2017 |
IntelGenx Receives Health Canada Clearance to Begin Phase 2a Study with Montelukast Versafilm(TM) in Mild to Moderate Al... |
|
11 |
Dec 2017 |
IntelGenx Receives USPTO Notice of Allowance for Montelukast Orange Book Eligible Patent... |
|
05 |
Dec 2017 |
IntelGenx to Regain Exclusive Worldwide Rights to Develop and Commercialize RIZAPORT(R)... |
|
09 |
Nov 2017 |
IntelGenx Reports Third Quarter 2017 Financial Results... |
|
09 |
Nov 2017 |
IntelGenx Submits Montelukast VersaFilm(TM) Clinical Trial Application With Health Canada... |
|
02 |
Nov 2017 |
IntelGenx to Report Third Quarter 2017 Financial Results on November 9, 2017 - Conference Call to Follow... |
|
01 |
Nov 2017 |
IntelGenx and RedHill Biopharma Resubmit RIZAPORT® New Drug Application to the FDA... |
|
06 |
Sep 2017 |
IntelGenx Announces Decisions in Suboxone(R) Patent Litigation... |
|
31 |
Aug 2017 |
IntelGenx Grants Stock Options... |
|
30 |
Aug 2017 |
IntelGenx to Present at the 19th Annual Rodman & Renshaw Global Investment Conference... |
|
10 |
Aug 2017 |
IntelGenx Reports Second Quarter 2017 Financial Results... |
|
08 |
Aug 2017 |
IntelGenx Closes Second Tranche of Convertible Debenture Offering... |
|
03 |
Aug 2017 |
IntelGenx to Report Second Quarter 2017 Financial Results on August 10, 2017 - Conference Call to Follow... |
|
12 |
Jul 2017 |
IntelGenx Completes CDN$6.8 Million Convertible Debenture Offering... |
|
12 |
Jul 2017 |
IntelGenx Presents at BIT's 7th Annual International Symposium of Drug Delivery Systems... |
|
29 |
Jun 2017 |
IntelGenx Files Final Short Form Prospectus In Connection With Offering of Convertible Unsecured Debentures... |
|
27 |
Jun 2017 |
IntelGenx Receives USPTO Notice of Allowance for Oral Film Dosage Form Technology Patent... |
|
08 |
Jun 2017 |
IntelGenx Announces Issuance of US Patent for Topical Oral Film Technology... |
|
11 |
May 2017 |
IntelGenx Reports First Quarter 2017 Financial Results... |
|
04 |
May 2017 |
IntelGenx to Report First Quarter 2017 Financial Results on May 11, 2017 - Conference Call to Follow... |
|
13 |
Apr 2017 |
IntelGenx and RedHill Biopharma Announce Marketing Approval of RIZAPORT(R) for Migraines in Luxembourg... |
|
05 |
Apr 2017 |
IntelGenx Files Preliminary Short Form Prospectus in Connection With a Proposed Offering of Convertible Unsecured Debent... |
|
04 |
Apr 2017 |
IntelGenx Presents at the 13th International Conference on Alzheimer's and Parkinson's Diseases... |
|
03 |
Apr 2017 |
IntelGenx and Tetra Bio-Pharma Announce the Signing of a Definitive Agreement for the Development and Commercialization ... |
|
28 |
Mar 2017 |
Oral Film Exclusivity Granted to IntelGenx' VersaFilm(TM) for Tadalafil Erectile Dysfunction Dosing Patent... |
|
28 |
Mar 2017 |
IntelGenx Reports Fourth Quarter and Full-Year 2016 Financial Results... |
|
21 |
Mar 2017 |
IntelGenx to Report Fourth Quarter and Full Year 2016 Financial Results on March 28, 2017 - Conference Call to Follow... |
|
13 |
Mar 2017 |
IntelGenx Engages Kilmer Lucas for Cross-Border Investor Relations... |
|
09 |
Feb 2017 |
IntelGenx and Tetra Bio-Pharma Announce the Signing of a Term Sheet for the Development and Commercialization of a Drona... |
|
30 |
Jan 2017 |
IntelGenx to Webcast, Live, at VirtualInvestorConferences.com February 2... |
|
19 |
Jan 2017 |
IntelGenx Grants Stock Options... |
|
04 |
Jan 2017 |
IntelGenx Announces Definitive Agreement with Chemo Group for a Generic CNS Tablet... |